Article
Oncology
Alexander Cocks, Filippo Del Vecchio, Verena Martinez-Rodriguez, Monique Schukking, Muller Fabbri
Summary: This review article discusses the interaction between tumor-associated macrophages (TAMs) and cancer cells, with a focus on the pro-tumoral phenotype elicited by EV-contained miRNAs released by TAMs and transferred to cancer cells.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ferenc Sipos, Gyorgyi Muzes
Summary: Inflammatory processes and cancer stem cells (CSCs) play important roles in tumorigenesis. CSCs are associated with cancer properties such as metastasis, treatment resistance, and disease recurrence. This review explores the reciprocal interplay between CSCs and immune cells in the tumor microenvironment, highlighting how CSCs influence leukocyte reprogramming and promote pro-tumor immune cells. The study also emphasizes the potential of immune cells in eliminating CSCs, while addressing the immune evasion mechanisms in CSCs and their clinical implications.
Article
Genetics & Heredity
Noora Karim Ahangar, Mohammad Khalaj-Kondori, Nazila Alizadeh, Ahad Mokhtarzadeh, Amir Baghbanzadeh, Mahdi Abdoli Shadbad, Katayoun Dolatkhah, Behzad Baradaran
Summary: This study found that tumor-intrinsic HHLA2 knockdown increases the anti-tumoral effect of paclitaxel on MG-63 cells and enhances the chemosensitivity of MG-63 cells to paclitaxel.
Article
Immunology
Raissa Timmerman, Ella A. Zuiderwijk-Sick, Jeffrey J. Bajramovic
Summary: TLR-induced signaling triggers inflammatory responses, and the P2Y6 receptor enhances pro-inflammatory cytokine levels, especially in microglia. Through transcriptome analysis, P2Y6 signaling amplifies pro-inflammatory responses in microglia by regulating the expression of target genes through modulation of transcription factors. Additionally, inhibition of P2Y6 signaling strongly induces heat shock protein expression. These findings shed new light on the specific pro-inflammatory role of P2Y6 signaling in neuroinflammation and may provide novel approaches to control brain inflammatory responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Alicia Cristina Pena-Romero, Esteban Orenes-Pinero
Summary: The relationship between the immune system and tumours is a crucial topic in cancer research. Immune cells in the tumour microenvironment can either support anti-tumour immunity or promote tumour progression. Understanding the influence of the tumour microenvironment on immune cells is essential for developing effective cancer treatments.
Review
Biotechnology & Applied Microbiology
Haojie Ding, Songrui Wu, Zi Jin, Bin Zheng, Yuan Hu, Ke He, Shaohong Lu, Xunhui Zhuo
Summary: Protozoan parasites can activate and enhance the immune system to inhibit tumor growth and metastasis, potentially becoming a key element in future anti-tumor treatments.
BIOENGINEERING-BASEL
(2022)
Review
Immunology
Chenglin Lu, Ying Liu, Nasra Mohamoud Ali, Bin Zhang, Xiaonan Cui
Summary: Innate immune cells in the tumor microenvironment determine the occurrence and development of tumors by secreting various factors. Understanding their role can improve therapeutic approaches and prognosis. This review provides an overview of the biology, role, and immunotherapy of innate immune cells, aiming to guide future research and clinical trials.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
You Qin, Furong Lu, Kexing Lyu, Alfred E. Chang, Qiao Li
Summary: B cells have been controversial regarding their roles in tumor immunity, but recent studies have shown their positive properties in antitumor immunity. Higher density of intratumoral B cells has been associated with favorable outcomes in cancer patients. B cells can trigger antitumor humoral responses through various biological events, and they can also function as effector cells via direct tumor-killing, antigen-presenting activity, and production of tumor-specific antibodies. On the other hand, B cells can also have inhibitory functions as regulatory B cells. Understanding the bipolar properties of B cells and developing B cell-based immunotherapeutic strategies are important for promoting cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Audrey Wetzel, Francis Bonnefoy, Cecile Chague, Mathieu Vetter, Melanie Couturier, Blandine Baffert, Olivier Adotevi, Philippe Saas, Sylvain Perruche
Summary: Cancer is a result of cellular dysfunction and abnormal multiplication, and an inflammatory environment can both defend against and promote cancer cell progression. Current therapeutic strategies focus on enhancing the immune response, but limiting inflammation may be an innovative approach. This study investigates the impact of administering pro-resolving factors as a potential alternative therapy to control cancer progression.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, Research & Experimental
Guangtao Pan, Ping Zhang, Jingyi Yang, Yanran Wu
Summary: Appropriate inflammation helps the body fight harmful stimuli, but excessive or prolonged inflammation can be damaging. The process of inflammation regression is active, and specialized pro-resolving mediators (SPMs) play a crucial role in this process. Evidence shows that exogenous treatment with SPMs can effectively improve inflammatory-related diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Y. Morera-Diaz, C. Canaan-Haden, J. Sanchez-Ramirez, M. Bequet-Romero, I. Gonzalez-Moya, R. Martinez, V. Falcon, D. Palenzuela, M. Ayala-Avila, J. V. Gavilondo
Summary: This paper reported the development of PKPD-L1(Vac), a new protein vaccine candidate for cancer treatment. The vaccine induced specific immune responses in mice and non-human primates, showing promising preclinical results. It is suggested that the vaccine should move forward to a phase I clinical trial.
Article
Multidisciplinary Sciences
Crismita Dmello, Junfei Zhao, Li Chen, Andrew Gould, Brandyn Castro, Victor A. Arrieta, Daniel Y. Zhang, Kwang-Soo Kim, Deepak Kanojia, Peng Zhang, Jason Miska, Ragini Yeeravalli, Karl Habashy, Ruth Saganty, Seong Jae Kang, Jawad Fares, Connor Liu, Gavin Dunn, Elizabeth Bartom, Matthew J. Schipma, Patrick D. Hsu, Mahmoud S. Alghamri, Maciej S. Lesniak, Amy B. Heimberger, Raul Rabadan, Catalina Lee-Chang, Adam M. Sonabend
Summary: This study identifies Chek2 as the most important kinase that promotes evasion of glioma cells from immune recognition. Genetic depletion or pharmacological inhibition of Chek2 enhances antigen presentation, STING pathway activation, and PD-L1 expression, leading to survival benefits in preclinical glioma models. Analysis of human GBMs shows a negative correlation between Chek2 expression and antigen presentation/T-cell activation. These results suggest that Chek2 may be a promising target for improving response to immune checkpoint blockade therapy.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Asif Sukri, Alfizah Hanafiah, Nik Ritza Kosai
Summary: Gastric cancer remains a leading cause of cancer-related death in developing countries, while immunotherapy has shown promising results in improving prognosis. Research on the roles of immune cells in gastric cancer pathogenesis is vital for developing effective immunotherapy strategies.
Article
Oncology
Camille Fuselier, Sandrine Quemener, Eleonore Dufay, Camille Bour, Camille Boulagnon-Rombi, Nicole Bouland, El-Hadi Djermoune, Jerome Devy, Laurent Martiny, Christophe Schneider
Summary: Melanoma, the most aggressive form of skin cancer, relies heavily on angiogenesis for progression. Low-diluted Phenacetinum shows promising anti-tumoral effects in inhibiting melanoma growth and metastasis through regulating blood vessel formation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
G. Boulle, Y. Velut, A. Mansuet-Lupo, L. Gibault, H. Blons, L. Fournel, A. Boni, I. Cremer, M. Wislez, V. Duchatelle, J. Tredaniel, S. A. Hammond, R. Herbst, M. Alifano, P. Giraud, D. Damotte
EUROPEAN JOURNAL OF CANCER
(2020)
Review
Immunology
Jules Russick, Carine Torset, Edouard Hemery, Isabelle Cremer
SEMINARS IN IMMUNOLOGY
(2020)
Article
Oncology
Jules Russick, Pierre-Emmanuel Joubert, Melanie Gillard-Bocquet, Carine Torset, Maxime Meylan, Florent Petitprez, Marie-Agnes Dragon-Durey, Solenne Marmier, Aditi Varthaman, Nathalie Josseaume, Claire Germain, Jeremy Goc, Marie-Caroline Dieu-Nosjean, Pierre Validire, Ludovic Fournel, Laurence Zitvogel, Gabriela Bindea, Audrey Lupo, Diane Damotte, Marco Alifano, Isabelle Cremer
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Medicine, Research & Experimental
Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Severine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camelia Radulescu, Sophie Ferlicot, David J. Figueroa, Sapna Yadavilli, Jeremy D. Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, Francois Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice Andre, Cedric Lebacle, Herve Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean-Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurelien Marabelle, Melodie Bonvalet, Laurence Zitvogel
Summary: Decision making in immuno-oncology plays a crucial role in adapting therapy to the tumor microenvironment. A multiplex functional and dynamic immuno-assay has been developed to predict unresponsiveness to anti-PD-1 mAbs and detect personalized combinatorial regimens in human primary tumors, awaiting validation in prospective clinical trials.
EMBO MOLECULAR MEDICINE
(2021)
Article
Multidisciplinary Sciences
Marie-Agnes Dragon-Durey, Xiaoyi Chen, Amos Kirilovsky, Nadine Ben Hamouda, Carine El Sissy, Jules Russick, Etienne Charpentier, Yannick Binois, Florence Marliot, Maxime Meylan, Clemence Granier, Helene Pere, Antonin Saldmann, Bastien Rance, Anne Sophie Jannot, Stephanie Baron, Mouna Chebbi, Antoine Fayol, Nathalie Josseaume, Claire Rives-Lange, Pierre-Louis Tharaux, Bernard Cholley, Jean-Luc Diehl, Jean-Benoit Arlet, Michel Azizi, Alexandre Karras, Sebastien Czernichow, David M. Smadja, Jean-Sebastien Hulot, Isabelle Cremer, Eric Tartour, Elie Mousseaux, Franck Pages
Summary: This study investigated the mechanisms underlying SARS-CoV-2 infection severity in patients with obesity. It found specific associations between inflammatory cytokines and liver, renal, and endothelial dysfunctions in obese patients, and independent correlations between early lung damage and obesity with cytokine levels. These findings highlight distinct pathophysiological mechanisms associated with SARS-CoV-2 infection in obese patients.
Article
Oncology
Marie V. Daugan, Margot Revel, Romane Thouenon, Marie-Agnes Dragon-Durey, Tania Robe-Rybkine, Carine Torset, Nicolas S. Merle, Remi Noe, Virginie Verkarre, Stephane Marie Oudard, Arnaud Mejean, Pierre Validire, Xavier Cathelineau, Rafael Sanchez-Salas, Mathew C. Pickering, Isabelle Cremer, Audrey Mansuet-Lupo, Marco Alifano, Catherine Sautes-Fridman, Diane Damotte, Wolf H. Fridman, Lubka T. Roumenina
Summary: The study reveals the impact mechanism of the master complement regulator factor H (FH) in clear cell renal cell carcinoma and lung cancer. FH exerts a protumoral action through an intracellular, noncanonical mechanism, affecting cell proliferation, migration, and cell cycle regulation. Intracellular FH plays a role in tumor progression in specific types of cancer, suggesting its potential as a prognostic biomarker or therapeutic target.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Marie V. Daugan, Margot Revel, Jules Russick, Marie-Agnes Dragon-Durey, Christine Gaboriaud, Tania Robe-Rybkine, Victoria Poillerat, Anne Grunenwald, Guillaume Lacroix, Antoine Bougouin, Maxime Meylan, Virginie Verkarre, Stephane M. Oudard, Arnaud Mejean, Yann A. Vano, Geraldine Perkins, Pierre Validire, Xavier Cathelineau, Rafael Sanchez-Salas, Diane Damotte, Veronique Fremeaux-Bacchi, Isabelle Cremer, Catherine Sautes-Fridman, Wolf H. Fridman, Lubka T. Roumenina
Summary: The complement system and C1s play important roles in clear cell renal cell carcinoma, with high C1s expression potentially promoting tumor progression.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Immunology
Jules Russick, Pierre-Emmanuel Foy, Nathalie Josseaume, Maxime Meylan, Nadine Ben Hamouda, Amos Kirilovsky, Carine El Sissy, Eric Tartour, David M. Smadja, Alexandre Karras, Jean-Sebastien Hulot, Marine Livrozet, Antoine Fayol, Jean-Benoit Arlet, Jean-Luc Diehl, Marie-Agnes Dragon-Durey, Franck Pages, Isabelle Cremer
Summary: Analysis of immune biomarkers in hospitalized COVID-19 patients reveals two categories, with those showing abnormal immune responses experiencing more severe disease. A proposed SARS-Score based on quantifiable biomarkers allows for classification and tailored treatment based on immune profile upon hospital admission.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Adrien Joseph, Pan Juncheng, Michele Mondini, Nizar Labaied, Mauro Loi, Julien Adam, Antoine Lafarge, Valentina Astesana, Florine Obrist, Christophe Klein, Norma Bloy, Gautier Stoll, Nicolas Signolle, Catherine Genestie, Diane Damotte, Marco Alifano, Alexandra Leary, Patricia Pautier, Philippe Morice, Sebastien Gouy, Eric Deutsch, Cyrus Chargari, Marie-Caroline Dieu-Nosjean, Isabelle Cremer, Judith Michels, Guido Kroemer, Maria Castedo
Summary: Tumors adapt their metabolism to resist therapeutic interventions like cisplatin, affecting the local immunosurveillance. This study found that PDXK and PAR levels impact the response to cisplatin, providing new insights into therapeutic failures in cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, Research & Experimental
Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert
Summary: Autophagy is a crucial process for cellular homeostasis and plays a dual role in tumor progression. It can limit early-stage carcinogenesis while promoting tumor growth and therapy resistance at later stages. Viral infections can modulate autophagy and have significant impacts on tumor behavior.
M S-MEDECINE SCIENCES
(2022)
Review
Oncology
Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert
Summary: Autophagy plays a crucial role in tumor development, influencing tumor transformation, survival, and resistance to treatment. Additionally, the association between viral infection and autophagic modulation can impact tumor behavior by affecting the fate of tumor cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert
Summary: The role of autophagy in lung cancer is still debated. This study focuses on the expression of autophagy genes in lung cancer patients and identifies an autophagy signature that correlates with the metabolic and immunogenic status of malignant cells. These findings support the relationship between autophagy and tumor growth in lung cancer patients.
News Item
Oncology
Lubka T. Roumenina, Isabelle Cremer
Summary: A new study shows that intratumoral activation of the complement cascade may be a potential therapy for lung cancer patients with strong EGFR signaling. The expression of CD55 and CD59 triggered by EGFR prevents opsonization of tumor cells, inhibits antitumor immunity, and confers resistance to immune-checkpoint inhibitors.
Article
Oncology
Yoan Velut, Elise Decroix, Helene Blons, Marco Alifano, Karen Leroy, Florent Petitprez, Aurelie Boni, Simon Garinet, Jerome Biton, Isabelle Cremer, Marie Wislez, Pascaline Boudou-Rouquette, Jennifer Arrondeau, Francois Goldwasser, Ludovic Fournel, Diane Damotte, Audrey Mansuet-Lupo
Summary: SMARCA4/BRG1 loss is common in NSCLC and is associated with high-grade adenocarcinomas and pleomorphic carcinomas. SD-NSCLC patients have an immunosuppressive environment characterized by increased FOXP3+ cells and neutrophil densities. SD-NSCLC patients have a poor prognosis and limited response to PD1 inhibitors.
Meeting Abstract
Oncology
Yoan Velut, Geoffroy Boulle, Audrey Mansuet Lupo, Laure Gibault, Helene Blons, Jean Tredaniel, Ludovic Fournel, Aurelie Boni, Isabelle Cremer, Marie Wislez, Veronique Duchatelle, Scott Hammond, Marco Alifano, Philippe Giraud, Diane Damotte